Price (delayed)
$14.38
Market cap
$135.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.37
Enterprise value
$124.13M
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the ...
Highlights
KRRO's EPS has shrunk by 107% QoQ but it has soared by 82% YoY
KRRO's net income is up by 4.8% since the previous quarter but it is down by 3% year-on-year
Korro Bio's debt has increased by 35% YoY and by 7% from the previous quarter
KRRO's quick ratio is down by 22% since the previous quarter
Key stats
What are the main financial stats of KRRO
MarketValuationsEarnings
Shares outstanding
9.39M
Market cap
$135.01M
Enterprise value
$124.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
56.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.66
Revenue
$2.27M
Gross profit
$2.27M
Operating income
-$91.91M
Net income
-$83.58M
EBIT
-$83.44M
EBITDA
-$76.56M
Free cash flow
-$77.98M
Per shareBalance sheetLiquidity
EPS
-$9.37
EPS diluted
-$9.37
Free cash flow per share
-$8.74
Book value per share
$17.12
Revenue per share
$0.25
TBVPS
$25.36
Total assets
$226.24M
Total liabilities
$65.83M
Debt
$44.77M
Equity
$160.42M
Working capital
$116.57M
Debt to equity
0.28
Current ratio
8.79
Quick ratio
8.54
Net debt/EBITDA
0.14
MarginsEfficiencyDividend
EBITDA margin
-3,371.2%
Gross margin
100%
Net margin
-3,680.4%
Operating margin
-4,047.1%
Return on assets
-36.4%
Return on equity
-48.5%
Return on invested capital
-49.8%
Return on capital employed
-39.5%
Return on sales
-3,674.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRRO stock price
How has the Korro Bio stock price performed over time
Intraday
-2.51%
1 week
-17.55%
1 month
-34.01%
1 year
-79.86%
YTD
-62.23%
QTD
-17.4%
Financial performance
How have Korro Bio's revenue and profit performed over time
Revenue
$2.27M
Gross profit
$2.27M
Operating income
-$91.91M
Net income
-$83.58M
Gross margin
100%
Net margin
-3,680.4%
KRRO financials
KRRO's operating income is down by 9% year-on-year but it is up by 4% since the previous quarter
KRRO's net income is up by 4.8% since the previous quarter but it is down by 3% year-on-year
Growth
What is Korro Bio's growth rate over time
KRRO growth chart
Valuation
What is Korro Bio stock price valuation
P/E
N/A
P/B
0.84
P/S
56.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.66
Price to earnings (P/E)
KRRO's EPS has shrunk by 107% QoQ but it has soared by 82% YoY
Price to book (P/B)
The stock's price to book (P/B) is 68% less than its last 4 quarters average of 2.6 and 58% less than its 5-year quarterly average of 2.0
Korro Bio's equity has decreased by 11% from the previous quarter and by 6% YoY
Price to sales (P/S)
Efficiency
How efficient is Korro Bio business performance
KRRO's ROIC has soared by 70% YoY and by 24% from the previous quarter
The return on equity has surged by 54% year-on-year and by 3.4% since the previous quarter
KRRO's return on assets is up by 50% year-on-year and by 5% since the previous quarter
Dividends
What is KRRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRRO.
Financial health
How did Korro Bio financials performed over time
Assets vs liabilities
KRRO's total liabilities is up by 27% YoY and by 3% QoQ
The current ratio has contracted by 22% from the previous quarter
Debt vs equity
Korro Bio's debt is 72% less than its equity
KRRO's debt to equity is up by 40% year-on-year and by 22% since the previous quarter
Korro Bio's debt has increased by 35% YoY and by 7% from the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.